期刊文献+

阿折地平与马来酸复合物的制备与表征 被引量:1

Synthesis and Characterization on Complex of Azelnidipine with Maleic Acid
暂未订购
导出
摘要 采用溶剂辅助研磨法制备了阿折地平-马来酸复合物,应用XRD,DSC,IR,Raman,THz,ssNMR等手段对复合物进行表征,以探讨阿折地平与马来酸之间作用力的类型;采用溶解度方法推导和计算了二者在溶液中形成的热力学公式和参数;采用高效液相(HPLC)法测定了阿折地平的含量.在苯辅助研磨的条件下,阿折地平与马来酸以2∶1的物质的量比形成了新的复合物.热力学分析表明二者结合的强度较高,结合常数达105数量级. The complex built upon azelnidipine grinding method and was characterized by powder and maleic acid was synthesized by using solvent-assisted X-ray diffraction (PXRD),differential scanning calorim- etry (DSC),infrared (IR) and Raman spectrum, solid-state nuclear magnetic resonance (ssNMR),and ter- ahertz (THz) spectroscopy. The formation thermodynamics of the azelnidipine-maleie acid complex were extensively investigated by solubility method. The concentrations of azelnidipine were determined by HLPC method. New azelnidipine-maleic acid complex was formed at a molar ratio of 2 ~ I by toluene-assisted co- grinding. The interactions between azelnidipine and maleic acid were discussed. Thermodynamics analysis indicated that the complex force between them was intense;the complex constants K were evaluated to be 10s orders of magnitude.
出处 《河北师范大学学报(自然科学版)》 CAS 北大核心 2013年第3期280-286,共7页 Journal of Hebei Normal University:Natural Science
基金 国家自然科学基金(81202504) 河北省科技支撑项目(12276402D) 河北省教育厅重点项目(2009148)
关键词 阿折地平 复合物 太赫兹谱 固态核磁 热力学 azelnidipine complex THz spectra solid state NMR thermodynamics
  • 相关文献

参考文献14

  • 1LIMWIKRANT W, HIGASHI K, YAMAMOTO K,et al. Characterization of Ofloxacin-oxalic Acid Complex by PXRD, NMR and THz Spectroscopy [J]. Int J Pharm, 2009,382:50-55.
  • 2BLAGDEN N, MATAS M,GAVAN P T,et al. Crystal Engineering of Active Pharmaceutical Ingredients to Improve Sol- ubility and Dissolution Rates[J]. Adv Drug Deliv Rev, 2007,59 :617-630.
  • 3STANTON M K,BAK A. Physicochemical Properties of Pharmaceutical Co-crystals..A Case Study of Ten AMG 517 Co- crystals[J]. Crystal Growth & Design,2008,8(10) :3856-3862.
  • 4UENO Y,AJITO K. Analytical Terahertz Spectroscopy [J]. Anal Sci,2008,24:185-192.
  • 5TADAY P F, BRADLEY I V, ARNONE D D, et al. Using Terahertz Pulsespeetroscopy to Study the Crystalline Structure of a Drug:A Case Study of the Polymorphs of Ranitidine Hydrochloride [J]. J Pharm Sci,2003,92:831-838.
  • 6LI D,WANG M, YANG C Q,et al. Solid State Characterizations and Analysis of Stability in Azelnidipine Polymorphs [J]. Chem Pharm Bu11,2012,60(8):995-1002.
  • 7YANG C Q, ZHANG Z W, ZENG Y L, et al. Structure Characterization of m-nisoldipine Polymorphs [J]. Cryst Eng Comm,2012,14 : 2589-2594.
  • 8贾静,南峰,梁茂植,余勤,秦永平,向瑾.高效液相色谱-串联质谱法测定人血浆中阿折地平浓度及药动学[J].中国医院药学杂志,2010,30(24):2088-2091. 被引量:3
  • 9LIAN Weiguang,LIN Yulong, WANG Min,et al. Crystal Engineering: Approach to Produce Complex of Azelnidipine with Maleic Acid [J]. Cryst Eng Comm,2013,Cite this DOh 10. 1039/c3ce26967a.
  • 10LARA O F, ESPINOSA P G. Co-crystals Definitions [J]. Supramol Chem, 2007,19(8) :553-557.

二级参考文献54

  • 1邹建军,朱余兵,于翠霞,肖大伟,王文涛,顾小祥,吴鹤鸣,路远,谷祥富.液相色谱-质谱法测定人血浆中阿折地平的浓度及其药动学[J].中国新药与临床杂志,2007,26(1):36-39. 被引量:5
  • 2Walsh R B, Padgett C W, Metrangolo P, et al. Crystal Growth & Design, 2001, 1(2) : 165-175.
  • 3Oswald I, Motherwell W, Parsons S. Acta Crystallographica Section E: Structure Reports Online, 2004, 60 ( 11 ) : 1967- 1969.
  • 4Almarsson Z M. Chemical Communications, 2004, 1889-1896.
  • 5Caira M. Mol. Pharma. , 2007, 4:310-316.
  • 6Aaker~y C. Acta Crystaltographica Section B: Structural Science, 1997, 53 (4): 569-586.
  • 7Blagden N, De Matas M, Gavan P, et al. Advanced Drug Delivery Reviews, 2007, 59(7): 617-630.
  • 8Huang C, Leiserow L, Schmidt G. J. Chem. Soc. , 1973, 2: 503 -508.
  • 9Remenar J, Morissette S, Peterson M, et al. Journal of the American Chemical Society, 2003, 125 (28) : 8456-8457.
  • 10Childs S, Chyall L, Dunlap J, et al. Journal of the American Chemical Society, 2004, 126(41): 13335-13342.

共引文献57

同被引文献18

  • 1李学明,张慧颖,陈国广,丁丽燕,韦萍.羟丙基-β-环糊精对酮洛芬的包合作用[J].中国药科大学学报,2006,37(1):37-40. 被引量:5
  • 2王建华,宋爱晶.一种新型辅料磺丁基醚-β-环糊精的药学应用进展[J].材料导报,2007,21(3):40-43. 被引量:27
  • 3Loftsson T, Brewster ME, Masson M. Role of cyclodextrins in improving oral drug delivery[J]. Am J Drug Deliv, 2004, 2(4):261-275.
  • 4Luke DR, Tomaszewski K, Damle B, et al. Review of the basic and clinical pharmacology of sulfobutyl ether-β-cyclodextrin(SBECD)[J]. J Pharm Sci, 2010, 99(8):3291-3301.
  • 5Burger A, Ramberger R. On the polymorphism of pharmaceuticals and other molecular crystals. I[J]. Mikrochim Acta, 1979, 72(3):259-271.
  • 6Takeru H, Kenneth A. Connors phase-solubility techniques[J]. Adv Anal Chem Instr, 1965, 4:117-125..
  • 7Qiu N, Cheng X, Wang GC, et al. Inclusion complex of barbigerone with hydroxypropyl-cyclodextrin:preparation and in vitro evaluation[J]. Carbohyd Polym, 2014, 101:623-630.
  • 8Dong LN, Liu M, Chen AJ, et al. Solubilities of quercetin in three β-cyclodextrin derivative solutions at different temperatures[J]. J Mol Liq, 2013,177:204-208.
  • 9Li JF, Wei YX, Ding LH, et al. Study on the inclusion complexes of cryptotanshinone with β-cyclodextrin and hydroxypropyl-β-cyclodextrin[J]. Spetrochim Acta Part A, 2003, 59(14):2759-2766.
  • 10Al Omari MM, Zughui MB, Davies JED, et al. Thermodynamic enthalpy-entropy compensation effects observed in the complexation of basic drug substrates with β-cyclodextrin[J]. J Incl Phenom Macrocycl Chem, 2007, 57(3):379-384.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部